Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half.
- AFib ablation outcomes usually face attrition over time and many patients experience arrhythmia recurrence despite successful pulmonary vein isolation.
- While observational studies suggest lifestyle modification reduces post-ablation recurrence, we lacked the RCT evidence to support systematic risk factor management.
That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with symptomatic nonpermanent AFib, a BMI ≥27, and additional cardiometabolic risk factors to either a structured physician-led risk factor management clinic or usual care.
After 12 months the benefits were clear…
- The study’s primary endpoint of arrhythmia freedom at 12 months was achieved by 61.3% in the lifestyle management group versus 40% with usual care.
- Recurrent arrhythmia hazard over 12 months was nearly halved with lifestyle management compared to usual care (HR 0.53).
- AFib symptom severity improved significantly with lifestyle intervention (mean difference: −2.0).
- Risk factor improvements were also substantial, including a 9kg greater weight loss, 7cm greater waist reduction, and 10.8 mmHg greater systolic BP reduction
Even with guideline-directed AFib care provided to both groups, the behavior modification approach produced dramatically better outcomes through tailored interventions targeting modifiable cardiometabolic factors such as diet and exercise.
- Both groups underwent pulmonary vein isolation with additional ablation at electrophysiologist discretion, and both received blinded guideline-directed AF management—isolating lifestyle modification as the intervention.
- The usual care group received risk factor management information but lacked enrollment in the structured clinic program, representing typical real-world practice.
Given that most AFib ablation patients have elevated BMI and other cardiometabolic risks, these findings suggest current practices underutilize a potent intervention that could nearly double long-term ablation success rates.
- The trial’s open-label design reflects real-world implementation where lifestyle programs cannot be blinded, though outcome assessment remained blinded to randomization.
The Takeaway
The results from ARREST-AF are a reminder that no amount of procedures or ablation technology improvements will ever outweigh the importance of a healthy lifestyle. They also provide yet another sign that in order for a patient’s long-term AFib outcomes to improve, their long-term health behaviors must improve too.
